Follow the decision all the way through
A medicines decision should do more than survive a meeting. It should give the people involved a clear reason to act, a practical account of the work and a way to examine the result.
PHARMORIS is being developed as the Medicines Action Layer around that journey. The starting point is a consequential question in a real organisation. The purpose is to keep the evidence, professional judgement and work that follows connected.
Start with the decision somebody needs to make
A pharmacy owner may be considering a new service. A provider medicines team may be examining a generic-medicines opportunity. A network may be asking why an agreed process succeeds in some branches and struggles in others. The setting shapes the question.
Define what is being decided, who has authority and how the organisation works today. Agree what a worthwhile improvement would look like. This gives the discussion a useful centre and makes it easier to recognise when the proposed answer has drifted away from the original need.
Build a case people can challenge
Bring together the sources, local context, alternatives and assumptions that matter to that decision. A price difference, a national trend and a published recommendation answer different questions. Their relevance has to be established for the setting in which somebody intends to act.
The product direction is a case that a qualified reviewer can interrogate. Where did a statement come from? Which conditions support it? What remains unknown? A useful review can identify a stronger option, narrow the proposal or show why more evidence is needed before proceeding.
Make professional judgement part of the journey
The person reviewing the case needs room to disagree. They may challenge an assumption, ask for another comparison, identify an exception or decide that the proposed change is inappropriate. That judgement should shape what happens next.
Different people carry different responsibilities. Pharmacy can examine medicines appropriateness; operational colleagues can examine delivery; finance can examine resources and affordability. Agreement becomes more meaningful when each person understands the decision they own and the evidence on which they are being asked to rely.
Bring the practical work into view
An agreed change can depend on training, communication, supply arrangements, local approval and staff capacity. These requirements belong in the case while the proposal can still be changed. Discovering them after approval can leave an attractive idea with no workable route into practice.
A useful plan makes the next action, its owner and its dependencies clear. It also explains what would prompt another review. A pharmacy group should be able to ask what branches need from headquarters; a hospital team should be able to see which decisions require clinical, operational or financial agreement.
The next action needs a route.
A recommendation needs someone able to act on it, the inputs they require and a way to see what happened next. PHARMORIS’s public proposition is built around that connection.
Walk through the public evidence, action, value and assurance story. The diagram explains the commercial idea; it does not expose private software architecture or represent a customer deployment.
Image source and contextLicensed medicine-pack photograph. No named medicine, stock availability or PHARMORIS deployment established.
The Medicines Action Layer
Keep the question,
the decision and
the work connected.
The reasoning behind a change. The people responsible for it. The work that follows, and a return to what actually happened.
The evidence
What makes this evidence useful here?
Medicine does not move forward on a convincing sentence alone. A useful case connects a real question to the evidence behind it.
Who does the evidence concern? When was it published? Does its setting match the organisation considering the change? Relevance is part of the reasoning.
PHARMORIS’s direction is to keep sources, interpretation and local assumptions distinguishable, so qualified people can examine the case and challenge what is missing.
That gives clinical, operational and financial colleagues a shared starting point: something they can interrogate, with the reasoning available for a closer look.
The responsible people
Who can move the decision forward?
A medicines decision passes through people with different responsibilities. The person who reviews a case may be different from the person who can approve or deliver it.
An action needs an owner, an appropriate review and a clear next conversation. A referral being sent is only one event in the work.
PHARMORIS focuses on making responsibility easier to follow across that journey, with professional judgement retained by the people qualified to exercise it.
Start with a question somebody already owns. Then bring the right clinical, operational and financial perspectives into the same account of what needs to happen.
The practical work
What will the change ask of the team?
A worthwhile proposal still has to fit a working day. Staff time, training, communication, approvals and supply all shape what is possible.
Those requirements deserve a place beside the evidence, where the team can see the dependencies and the effort expected of them.
The product ambition is to connect a proposed change with its practical work, from a single pharmacy to a service being considered across a network.
A useful plan explains who will act, what they need and which questions remain open. That makes the next conversation concrete.
The observed comparison
What happened against the original case?
Return to the original question. What changed in practice, what effort did it require, and what still needs a better answer?
Our planned evaluations compare PHARMORIS with competent existing work, including checking, correction, training and support across the complete task.
A faster draft is one observation. Clinical quality, team workload and economic value each need measures suited to the setting.
That comparison should help an organisation see where the approach adds value, where it needs to change and what would justify using it again.
One medicines question. A shared account of what follows.
Return to what actually happened
Completion and value deserve separate questions. Was the change introduced as intended? Did people use the new approach? What additional checking or support did it require? Which effects can reasonably be associated with the change?
Compare the result with the original case and a credible account of what would otherwise have happened. Retain the distinction between staff capacity, expenditure, service delivery and patient outcomes. A clear record is useful even when the result calls for adaptation or stopping: it gives the next decision better information.
NEUVIOR Data Analysis
A source.
A question.
A clearer decision.
Useful intelligence keeps its evidence attached.
Our public analysis connects a defined question with named sources, reporting periods and methods. Each source below shows the work available today and the access still needed.
Published-data analysis, research hypotheses and evidence studies are distinct kinds of work. Their meaning should remain clear as the programme grows.
NHS Business Services Authority | Annual
Prescription Cost Analysis
How does activity differ from ingredient-cost concentration?
Analysis availableNHS Business Services Authority | Monthly
English Prescribing Dataset with SNOMED Code
Which product and organisational patterns merit a closer investigation?
Metadata retrievedMedicines and Healthcare products Regulatory Agency | Event-driven; monthly roundup also published
Medicines and device safety communications
Which official communication should a responsible team read next?
Snapshot retrievedNHS Business Services Authority and NHS England | Weekly
Dictionary of medicines and devices
Can the same product identity be followed consistently across sources?
Access reviewUse an evaluation to sharpen the fit
Consider a team assessing a generic-medicines opportunity. Evidence preparation is one part of the task. Local suitability, supply conditions, professional review and implementation effort determine whether the opportunity deserves action. Subsequent review establishes what was actually introduced and observed.
This illustrates the intended journey, rather than an automatic medicine-switching service. A proposed evaluation agrees the task, available functions, permitted information and comparison with the participating organisation. The useful question is whether the complete workflow earns its place alongside competent existing practice.
Bring a decision with a reason to move
Tell us what your team is trying to decide, how you handle it today and which obstacle repeatedly holds the work back. An accountable owner and a clear outcome make a PHARMORIS briefing productive.
We can then examine the fit and the scope of a possible evaluation, including the professional input, resources and evidence a next step would require.
